Rocket Pharmaceuticals Inc. Common Stock (RCKT)

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

202

Website

www.rocketpharma.com/

Fundamentals

1-day range

$3.53$3.96

Market cap

$372.35M

P/E (trailing)

—

P/E (forward)

-2.96

EPS (trailing)

$-0.18

Dividend yield

—

Beta

0.46

Avg. volume

2.18M

Dividend pay date

January 5, 2018

Forecasts

11 analyst ratings

Rocket Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $376.57MP/E —
  $7.05$17.15
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $391.42MP/E 18.65
  $4.3$9.51
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $351.32MP/E —
  $5.14$10.42
• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $349.38MP/E —
  $5.85$33.68
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
  SeekingAlpha · 8/18/2026
• Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
  Benzinga · 8/11/2026
• Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
  Benzinga · 8/10/2026
• Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
  Benzinga · 8/3/2026
• Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
  Yahoo · 8/3/2026
• Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
  Benzinga · 8/3/2026

• Christopher James Stevens · August 11, 2026 · Sale

  36.7K @ $3.5
• Sarbani Chaudhuri · August 11, 2026 · Sale

  4.7K @ $3.5
• Christopher James Stevens · August 3, 2026 · Grant

  101.4K
• Christopher James Stevens · August 3, 2026 · Grant

  73.3K
• David P. Southwell · August 3, 2026 · J

  150.0K
• Roderick Wong · June 18, 2026 · Grant

  79.0K
• Roderick Wong · June 18, 2026 · Grant

  27.8K
• Peter Fong · June 18, 2026 · Grant

  64.9K
• Peter Fong · June 18, 2026 · Grant

  22.9K
• Mikael Dolsten · June 18, 2026 · Grant

  64.9K
• Mikael Dolsten · June 18, 2026 · Grant

  22.9K
• Fady Ibraham Malik · June 18, 2026 · Grant

  64.9K
• Fady Ibraham Malik · June 18, 2026 · Grant

  22.9K
• Carsten Boess · June 18, 2026 · Grant

  64.9K
• Carsten Boess · June 18, 2026 · Grant

  22.9K

Institutional Ownership

March 31, 2026

Total shares held

91.44M

Total value held

$323.77M

Institutional holders

192